**Name of journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 36607**

**Manuscript Type: ORIGINAL ARTICLE**

***Observational Study***

**Influence of *NUDT15* variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines**

Kojima Y *et al*. Influence of *NUDT15* variants on IBD

Yuichiro Kojima, Yosuke Hirotsu, Wataru Omata, Makoto Sugimori, Shinya Takaoka, Hiroshi Ashizawa, Keiko Nakagomi, Dai Yoshimura, Kenji Hosoda, Yoji Suzuki, Hitoshi Mochizuki and Masao Omata

**Yuichiro Kojima, Shinya Takaoka, Hiroshi Ashizawa, Keiko Nakagomi, Dai Yoshimura, Kenji Hosoda, Yoji Suzuki,**Department of Gastroenterology, Yamanashi Prefectural Central Hospital,Yamanashi 400-8506, Japan

**Yosuke Hirotsu,** Genome Analysis Center, Yamanashi Prefectural Central Hospital, Yamanashi 400-8506, Japan

**Wataru Omata,** Department of Dermatologic Oncology, National Cancer Institute, Tokyo 104-0045, Japan

**Makoto Sugimori,** Division of Gastroenterology, Department of Medicine, Yokohama City University, Graduate School of Medicine, Kanagawa 236-0004, Japan

**Hitoshi Mochizuki,** Department of Gastroenterology, Genome Analysis Center, Yamanashi Prefectural Central Hospital, Yamanashi 400-8506, Japan

**Masao Omata,** Department of Gastroenterology, Genome Analysis Center, Yamanashi Prefectural Central Hospital,Yamanashi 400-8506, Japan

**ORCID number:** Yuichiro Kojima (0000-0003-4370-1651); Yosuke Hirotsu (0000-0002-8002-834X); Wataru Omata (0000-0002-4798-7552); Makoto Sugimori (0000-0001-5272-5167); Shinya Takaoka (0000-0003-0116-3605); Hiroshi Ashizawa (0000-0001-8649-4029); Keiko Nakagomi (0000-0001-4658-4833); Dai Yoshimura (0000-0002-5471-9948); Kenji Hosoda (0000-0002-9330-3152); Yoji Suzuki (0000-0002-5606-4834); Hitoshi Mochizuki (0000-0002-1145-0969); Masao Omata (0000-0001-7977-1497).

**Author contributions:** Kojima Y contributed to writing a paper and data acquisition and most of the patients were in his charge; Hirotsu Y, Omata W, Sugimori M and Takaoka S performed genome analysis; Ashizawa H, Nakagomi K, Yoshimura D, Hosoda K and Suzuki Y contributed to the treatment of patients; Mochizuki H contributed to the data analysis; Omata M contributed to the study conception, design, reviewing and final approval of the article.

**Institutional review board statement:** The protocol was approved by the Institutional Review Board of Yamanashi Prefectural Central Hospital.

**Informed consent statement:** Written informed consent to conduct genetic analysis of *NUDT15* and *TPMT* was obtained by all 96 patients.

**Conflict-of-interest** **statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Yuichiro Kojima, MD, PhD,** **Chief Doctor,** Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi 400-8506, Japan. y-kojima@ych.pref.yamanashi.jp

**Telephone:** +81-55-253-7111

**Fax:** +81-55-253- 8011

**Received:** October 16, 2017

**Peer-review started:** October 17, 2017

**First decision:** November 8, 2017

**Revised:** December 2, 2017

**Accepted:** December 5, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

The single nucleotide polymorphism (SNP) c.415C > T in exon 3 of *NUDT15* affects thiopurine-induced leukopenia in Asian patients with Crohn’s disease. Meanwhile, three additional genetic variants of *NUDT15* were reported in patients with acute lymphoblastic leukemia. We evaluated the effects of these additional genetic variants of *NUDT15* in patients with inflammatory bowel disease (IBD) treated with thiopurines.

***METHODS***

Ninety-six Japanese patients with IBD were enrolled. Genotyping for the *NUDT15* and *TPMT* genes was performed using Custom TaqMan SNP genotyping assays or Sanger sequencing. The changes in white blood cell (WBC) count, mean corpuscular volume (MCV), platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR were evaluated.

***RESULTS***

Genetic variants of exon 1 and exon 3 of *NUDT15* were identified in 24 of 96 patients (25.0%). C.52G > A and c.36\_37insGGAGTC in exon 1 were found in three patients each. All three patients with c.36\_37insGGAGTC in exon 1 were heterozygotes of p.Arg139Cys in exon 3. Eighteen patients had p.Arg139Cys in exon 3 alone. The WBC count gradually decreased after initiation of thiopurine treatment in the mutated cases (*n =* 24), and was significantly lower at 6, 8, 10, and 16 wk(*P =* 0.0271, 0.0037, 0.0051, and 0.0185, respectively). The WBC counts were also evaluated in patients with and without prednisolone treatment. In the patients with prednisolone treatment, the WBC count tended to show a greater decrease in the mutated cases, with significant differences at 8 and 10 wk (*P =* 0.012 and 0.029, respectively). In the patients without prednisolone treatment, the WBC count was significantly lower at 2, 4, 8, and 14 wk in mutated cases (*P =* 0.0196, 0.0182, 0.0237, and 0.0241, respectively). MCV increased after starting thiopurine treatment in the mutated cases, and was significantly higher at 10 wk (*P =* 0.0085). Platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR did not differ significantly between the wild-type and mutated cases. *TPMT* mutations were not found in any of the patients.

***CONCLUSIONS***

Mutations in exon 1 of *NUDT15* also affect thiopurine-induced leukopenia in patients with IBD. To discuss thiopurine-induced leukopenia in more detail, investigation of SNPs in both exon 1 and exon 3 of *NUDT15* is needed.

**Key Words:** Inflammatory bowel disease; *NUDT15*; Leukopenia; Mean corpuscular volume; Japanese

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Single nucleotide polymorphism (SNP) in *NUDT15* c.415C > T in exon 3 affects thiopurine-induced leukopenia in Asian Crohn’s disease patients. Meanwhile, there is a report of additional three genetic variants of *NUDT15* in patients with acute lymphoblastic leukemia. We evaluated the effect of these additional genetic variants of *NUDT15* on inflammatory bowel disease (IBD) treated with thyopurines. The increase rate of mean corpuscular volume was higher in the variants than the wild, Mutations of *NUDT15* in exon 1 also affects thiopurine-induced leukopenia in patients with IBD. To discuss thiopurine-induced leukopenia, investigating SNPs both exons 1 and exon 3 of *NUDT15* is needed.

Kojima Y, Hirotsu Y, Omata W, Sugimori M, Takaoka S, Ashizawa H, Nakagomi K, Yoshimura D, Hosoda K, Suzuki Y, Mochizuki H, Omata M. Influence of *NUDT15* variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. *World J Gastroenterol* 2017; In press

**Introduction**

The number of patients with inflammatory bowel disease (IBD) are increasing worldwide. As the treatment for ulcerative colitis (UC) and Crohn’s disease (CD), thiopurine drugs are widely used[1]. For UC, thiopurines are used for both steroid-dependent and steroid-resistant cases. For CD, thiopurines are recommended to be used with infliximab for better efficacy and prevention of events such as infusion reaction[2].

The reported major adverse events associated with thiopurines include leukopenia, pancreatitis, hair loss, and liver dysfunction[3,4]. In European descent, this leukopenia is mainly associated with genetic variations of *TPMT* which encodes thiopurine S-methyltransferase[5]. Meanwhile, in Asian patients, a single nucleotide polymorphism (SNP) in exon 3 of *NUDT15* c.415C > T (encoding p.Arg139Cys), was shown to play an important role in thiopurine-induced leukopenia[6-11]. When p.Arg139Cys occurred, the odds ratio of myelosuppression caused by thiopurines was 35.6 (*P =* 4.88 × 10-94) in Korean patients with CD[6].

Recently, three additional genetic variants of *NUDT15* were reported to induce leukopenia in patients with acute lymphoblastic leukemia (ALL)[12]. These three genetic variants were c.36\_37insGGAGTC (encoding p.Val18\_Val19insGlyVal) and c.52G > A (encoding p.Val18Ile) in exon 1 and c.416G > A (encoding p.Arg139His) in exon 3. However, these three SNPs were not examined in Asian patients with IBD.

In the present study, we investigated the effects of all four SNPs in exon 1 and exon 3 of *NUDT15* and their correlations with biochemical parameters. We also analyzed three SNPs in the *TPMT* gene that are associated with drug responses and commonly performed in Europe.

**MATERIALS AND METHODS**

***Patients***

We enrolled 96 Japanese patients with IBD treated with thiopurines at our hospital between October 2015 and January 2016. These 96 patients comprised 32 females and 64 males with a median age of 28 years at presentation of IBD. Sixty-seven patients had UC and 29 patients had CD (Table 1). The treatment protocols were as follows. All 96 patients were treated with 6-mercaptopurine (6MP), which was started at a dose of 30 mg daily. Ninety patients received 5ASA, 54 patients received steroid, and 36 patients received anti-TNF drugs (infliximab, 24; adalimumab, 7) (Table 1). Written informed consent to conduct genetic analysis of *NUDT15* and *TPMT* was obtained from all 96 patients.

Adverse events were examined every week for the first month and then every 1–2 mo thereafter. Blood samples were analyzed for white blood cell (WBC) count, hemoglobin, mean corpuscular volume (MCV), platelet count, amylase, lipase, AST, ALT, albumin, CRP, and ESR.

The protocol was approved by the Institutional Review Board of Yamanashi Prefectural Central Hospital.

***DNA extraction***

Peripheral blood samples were obtained from the 96 patients. Buffy coats were isolated by centrifugation of the blood samples at 820 × *g* at 25 °C for 10 min and stored at −80 °C until required for DNA extraction. Buffy-coat DNA was extracted using a QIAamp® DNA Blood Mini QIAcube Kit (Qiagen, Hilden, Germany) with a QIAcube (Qiagen). The total genomic DNA concentration was determined using a Nano Drop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) as described previously[13,14].

***Sanger sequencing***

PCR was performed using genomic DNA as a template and primer pairs flanking the SNP sites in exon 1 (rs869320766, p.Val18\_Val19insGlyVal; rs186364861, Val18Ile) and exon 3 (rs116855232, Arg139Cys; rs147390019, Arg139His) of the *NUDT15* gene. The PCR products were cleaned up using ExoSAP-IT™ Reagent (Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions. Sequencing was performed with a BigDye Terminator v3.1 (Thermo Fisher Scientific) using forward or reverse primers. The PCR products were purified and subsequently analyzed by a 3500 Genetic Analyzer (Thermo Fisher Scientific)[15,16]. The primer sequences are provided in Table 2.

***Single nucleotide polymorphism genotyping***

Real-time PCR was conducted in a ViiA7 system (Thermo Fisher Scientific) using TaqMan Genotyping Master Mix (1 ×) (Life Technologies Corp.), forward and reverse primers, and specific probes. SNP genotyping was conducted by the allelic discrimination method. *NUDT15* (rs186364861, Val18Ile; rs116855232, Arg139Cys) and *TPMT* (rs1800462, rs1800460, and rs1142345) genotyping primers and probes were purchased from Thermo Fisher Scientific. *NUDT15* SNP typing was validated by the Sanger sequencing results. The GenBank sequences of human *NUDT15* (accession number: NP\_060753.1) and *TPMT* (accession number: NP\_000358.1) were accessed at the NCBI Reference Sequence Database.

***Statistical analysis***

All statistical analyses were performed using R version 3.3.3. The statistical significance of differences in mean values between two cohorts was assessed by Student’s *t*-test if the variances were equal in an *F* test, or by the nonparametric Mann–Whitney test if the variances were not equal.

**ResultS**

Genetic variants of exon 1 and exon 3 of *NUDT15* were identified in 24 of 96 patients (25.0%) (Table 3). All mutated cases were heterozygotes. C.52G > A (p.Val18Ile) in exon 1 was found in three patients (Group A, Table 3). All three patients with c.36\_37insGGAGTC (p.Val18\_Val19insGlyVal) in exon 1 were heterozygotes for c.415C > T (p.Arg139Cys) in exon 3 (Group B, Table 3).

Eighteen patients had c.415C > T (p.Arg139Cys) in exon 3 alone (Group C, Table 3). The mutations p.Val18Ile and p.Val18\_Val19insGlyVal were mutually exclusive. *TPMT* mutations were not observed in any of the patients.

We investigated the changes in the WBC count. The WBC count gradually decreased after thiopurine treatment was started in both the mutated (*n =* 24) and wild-type (*n =* 72) cases (Figure 1A). The WBC count in the mutated cases was significantly lower at 6, 8, 10, and 16 wk(*P =* 0.0271, 0.0037, 0.0051, and 0.0185, respectively). To examine the decrease rates in the WBC count, we set the WBC count at the beginning of thiopurine treatment at 1.0. The decrease rate was higher in the mutated cases (*n =* 24) than in the wild-type cases (*n =* 72), and showed significant differences at 4, 6, 8, 10, 12, 14, and 16 wk (*P =* 0.004, 0.0001, 0.0012, 0.0022, 0.00001, 0.0264, and 0.0031, respectively, Figure 1b).

We also analyzed the WBC count in the patients with and without prednisolone treatment. In the patients with prednisolone treatment, the WBC count tended to show a greater decrease in the mutated cases (Group A + B + C), with significant differences at 8 and 10 wk (*P =* 0.012 and 0.029, respectively; Figure 2A). Prednisolone induced dynamic change of WBC counts which varied in each case. Statistical difference was only obtained at 8 and 10 wk. In the patients without prednisolone treatment, the WBC count was significantly lower at 2, 4, 8, and 14 wk in the mutated cases (Group A + B + C) compared with the wild-type cases (Group D; *P =* 0.0196, 0.0182, 0.0237, and 0.0241, respectively; Figure 2B).

Next, we divided the cases into three categories: Group A+B, Group C, and Group D (Figure 3A and B). Group C was already reported cases in IBD with c.415C > T in exon 3 of *NUDT15*. Group A + B did not show any significant differences from Group C, but had a lower WBC count compared with that in Group D.

As it is well known that thiopurines increase MCV[17], we analyzed the changes in MCV after initiation of thiopurine treatment. MCV increased after starting 6MP in both the mutated (Group A + B + C) and wild-type (Group D) cases (Figure 4A and B). MCV was significantly higher at 10 wk in the mutated cases compared with the wild-type cases (*P =* 0.0085; Figure 4A). To analyze the increase rate in MCV, we set the MCV at the beginning of thiopurine treatment at 1.0. The increase rate was higher in the mutated cases compared with the wild-type cases, and the difference was significant at 16 wk (*P =* 0.00198; Figure 4B).

We also investigated the changes in platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR, but did not observe any significant differences between the mutated and wild-type cases. *TPMT* mutations were not observed in any of the 96 patients.

**DISCUSSION**

The genotypes of *NUDT15* vary worldwide, according to the 1000 Genomes Project (<http://www.1000genomes.org/category/frequently-asked-questions/population>), 5000 Exomes Project (NHLBI ESP; https://esp.gs.washington.edu/drupal/), and The Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org). However, detailed information on the different types of *NUDT15* SNPs is not necessarily available for individual diseases.

Recently, new genotypes of *NUDT15* were reported in patients with ALL, including three genetic variants of *NUDT15* that induced leukopenia[12]. Until now, there have been several reports on analyses of *NUDT15* in patients with IBD. However, these studies only evaluated one SNP site (c.415C > T, encoding p.Arg139Cys) in exon 3[6,7,18]. Therefore, we analyzed the three additional genetic variants of *NUDT15*, namely c.36\_37insGGAGTC (encoding p.Val18\_Val19insGlyVal) and c.52G > A (encoding p.Val18Ile) in exon 1 and c.416G > A (encoding p.Arg139His) in exon 3, in patients with IBD.

In our 96 patients with IBD, we found six cases with exon 1 mutations. Three exon 1 mutated cases with c.36\_37insGGAGTC also had the c.415C > T mutation in exon 3. However, the other three exon 1 mutated cases with c.52G > A had the wild-type in exon 3. Consequently, without analysis of exon 1, 3.1% (3 of 96) of the patients at risk of thiopurine-induced leukopenia would have been missed. Regarding the mutations among the 24 patients with SNPs in either exon 1 or exon 3, 6 (25%) had mutations in exon 1. Thus, to fully evaluate thiopurine-induced leukopenia and other side effects, investigation of both exon 1 and exon 3 of *NUDT15* is necessary.

We also examined MCV and other variables. MCV tended to be higher in the *NUDT15* mutated cases than in the wild-type cases, with a significant difference at 10 wk after the start of thiopurine treatment. We didn’t measure the concentrations of folate and vitamin B12, which affect MCV. Before starting thiopurines, The MCV was in normal range. Previously it is reported that salazosulfapyridine, one of 5ASAs, decreased the absorption of folate, but the only nine patients were taking salazosulphapyridine and the MCV was also in normal range at the initiation of 6MP. MCV was previously shown to be positively correlated with the 6-thioguanine nucleotide (6-TGN) concentration in red blood cells[19]. The role of *NUDT15* SNPs is not totally understood. It was reported that *NUDT15* inactivates thiopurine metabolites and decreases thiopurine cytotoxicity *in vitro*, and that patients with defective *NUDT15* alleles had excessive levels of thiopurine active metabolites and toxicity[12]. Another study that evaluated 6-TGN levels found that thiopurine-induced leukopenia was independent of the 6-TGN concentration[7]. However, that study measured the total amount of 6-TGN and did not differentiate among thiopurine active metabolites (TGTP and DNA-6TG incorporation). Therefore, further investigations are necessary to examine the correlations of *NUDT15* SNPs and thiopurine metabolites, and hence the induction of side effects.

We also tested three SNPs of *TMPT*, and as previously reported, no TPMT variant was found. So it is not necessarily performed in Asian patients. Our results support previous data that *TPMT* variant is low in Asian patients.

Our study has several limitations. Firstly, the number of patients was too small to have definite conclusions. For example, the WBC count in patients with prednisolone treatment was not significant at time points other than 8 and 10 wk. We have not encountered any patients with agranulocytosis and severe hair loss If we were able to recruit more patients we may be able to obtain definite conclusions. Secondly, our study was a retrospective in nature, and therefore clinical utility of SNP analysis is not assured to avoid complications related to use of 6MP. Thirdly, we only observed the patients for 16 wk after initiation of thiopurine treatment, the long-term effects of thiopurines remain unclear. We are planning further studies to clarify these limitations.

Recently, three other *NUDT15* variants, c.101G > C (p.R34T), c.103A > G (p.K35E), and c.37\_42delGGAGTC (p.G17\_V18del), were reported in ALL patients[20]. By using next-generation sequencing, it will become easier to provide information on *NUDT15* SNPs despite changes in SNP numbers. Analysis of *NUDT15* should be routinely performed before starting thiopurine treatment in patients with IBD.

**ARTICLE HIGHLIGHTS**

***Research background***

Previous study demonatrated that single nucleotide polymorphism (SNP) in *NUDT15* c.415C > T (encoding p.Arg139Cys) in exon 3　affects thiopurine-induced leukopenia in Asian patients with inflammatory bowel disease (IBD). In acute lymphoblastic leukemia (ALL), there are other variants of *NUDT15* in exon1 and exon3. We demonstrated the variants of c.36\_37insGGAGTC (encoding p.Val18\_Val19insGlyVal) and c.52G > A (encoding p.Val18Ile) in exon 1 also affect the thiopurine-induced leukopenia. To present thiopurine-induced leukopenia and other side effects, checking both exons 1 and exon 3 of *NUDT15* is definitely needed.

***Research motivations***

It is well known that leukopenia is one of the most important adverse effects of tiopurines. To distinguish the high risk group of the adverse effects is clinically very important. Thus we investigated other *NUDT15* variants than *NUDT15* c.415 C > T in exon 3.

***Research objectives***

The main objectives, the objectives that were realized, and the significance of realizing these objectives for future research in this field should be described in detail.

***Research methods***

We enrolled 96 Japanese patients with IBD. Genotyping for *NUDT15* and *TPMT* genes was performed using Custom TaqMan SNP genotyping assays or Sanger sequencing. The changes of white blood cell (WBC) count, mean corpuscular volume (MCV), platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR were analyzed.

***Research results***

In 24 out of 96 c (25.0%), genetic variants of exons 1 and 3 were identified. C.52G > A and c.36\_37insGGAGTC in exon 1 was found in 3 cases each. All 3 cases of c.36\_37insGGAGTC in exon 1 had heterozygote of p.Arg139Cys in exon 3. Eighteen patients showed p.Arg139Cys in exon 3 alone. WBC count gradually decreased after thiopurine was started in the mutant (*n =* 24). The WBC count of the mutant was statistically significantly lower at 6, 8, 10 and 16 wk(*P =* 0.0271, 0.0037, 0.0051, and 0.0185, respectively). We also analyzed WBC count in the cases with and without prednisolone. In the cases with prednisolone, WBC count tended to decrease more in the mutant cases and was significantly lower at 8 and 10 wk (*P =* 0.012 and 0.029, respectively). In the cases without prednisolone, WBC count was significantly lower at 2, 4, 8 and 14 wk in the mutant than the wild cases (*P =* 0.0196, 0.0182, 0.0237 and 0.0241, respectively). MCV increased after starting thiopurine in the mutant. MCV was significantly higher at 10 wk in the mutant than the wild cases (*P =* 0.0085). Platelet count, hemoglobin, CRP, amylase, albumin, AST, ALT, and ESR was not different between the wild and the mutant cases. *TPMT* mutation was not found in any of our Japanese patients.

***Research conclusions***

We reported NUDT15 variant in exon1 also affect thiopurine-induced leukopnea in patients with IBD. Before starting the treatimet with thiopurines for patients with IBD, *NUDT15* variant in exon 1 and 3 will be routinely performed for preventing adverse events of thiopurines in the near future.

***Research perspectives***

There are other *NUDT15* variants which are reported in patients with ALL and near future their role on IBD patients will be investigated.

**ReferenceS**

1 **Amin J**, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. *Inflamm Bowel Dis* 2015; **21**: 445-452 [PMID: 25248004 DOI: 10.1097/mib.0000000000000197]

2 **Colombel JF**, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; **362**: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]

3 **Present DH**, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. *Ann Intern Med* 1989; **111**: 641-649 [PMID: 2802419]

4 **Meijer B**, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. *World J Gastroenterol* 2016; **22**: 9012-9021 [PMID: 27833392 DOI: 10.3748/wjg.v22.i40.9012]

5 Sandborn WJ. Pharmacogenomics and IBD: TPMT and thiopurines. *Inflammatory bowel diseases* 2004; **10**: S35-S37

6 **Yang SK**, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Park SK, Yang DH, Dubinsky M, Lee I, McGovern DP, Liu J, Song K. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. *Nat Genet* 2014; **46**: 1017-1020 [PMID: 25108385 DOI: 10.1038/ng.3060]

7 **Asada A**, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, Kito K, Sugimoto M, Andoh A. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. *J Gastroenterol* 2016; **51**: 22-29 [PMID: 26590936 DOI: 10.1007/s00535-015-1142-4]

8 **Chiengthong K**, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, Seksan P, Suppipat K, Suphapeetiporn K, Shotelersuk V. NUDT15 c.415C&gt;T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. *Haematologica* 2016; **101**: e24-e26 [PMID: 26405151 DOI: 10.3324/haematol.2015.134775]

9 **Yang JJ**, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. *J Clin Oncol* 2015; **33**: 1235-1242 [PMID: 25624441 DOI: 10.1200/jco.2014.59.4671]

10 **Shah SA**, Paradkar M, Desai D, Ashavaid TF. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. *J Gastroenterol Hepatol* 2017; **32**: 620-624 [PMID: 27416873 DOI: 10.1111/jgh.13494]

11 **Ailing Z**, Jing Y, Jingli L, Yun X, Xiaojian Z. Further evidence that a variant of the gene NUDT15 may be an important predictor of azathioprine-induced toxicity in Chinese subjects: a case report. *J Clin Pharm Ther* 2016; **41**: 572-574 [PMID: 27381176 DOI: 10.1111/jcpt.12420]

12 **Moriyama T**, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. *Nat Genet* 2016; **48**: 367-373 [PMID: 26878724 DOI: 10.1038/ng.3508]

13 **Hirotsu Y**, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. *Mol Genet Genomic Med* 2015; **3**: 121-129 [PMID: 25802882 DOI: 10.1002/mgg3.120]

14 **Sakamoto I**, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. *Cancer* 2016; **122**: 84-90 [PMID: 26439132 DOI: 10.1002/cncr.29707]

15 **Hirotsu Y**, Nakagomi H, Amemiya K, Oyama T, Inoue M, Mochizuki H, Omata M. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. *Med Oncol* 2017; **34**: 3 [PMID: 27900589]

16 **Hirotsu Y**, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H, Omata M. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. *Mol Genet Genomic Med* 2015; **3**: 459-466 [PMID: 26436112]

17 **Kopylov U**, Battat R, Benmassaoud A, Paradis-Surprenant L, Seidman EG. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. *Dig Dis Sci* 2015; **60**: 478-484 [PMID: 25236422 DOI: 10.1007/s10620-014-3362-5]

18 **Kakuta Y**, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H, Endo K, Negoro K, Kinouchi Y, Shimosegawa T. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. *Pharmacogenomics J* 2016; **16**: 280-285 [PMID: 26076924 DOI: 10.1038/tpj.2015.43]

19 **Meijer B**, Wilhelm AJ, Mulder CJJ, Bouma G, van Bodegraven AA, de Boer NKH. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. *Ther Drug Monit* 2017; **39**: 399-405 [PMID: 28489727 DOI: 10.1097/ftd.0000000000000414]

20 **Moriyama T**, Yang YL, Nishii R, Ariffin H, Liu C, Lin TN, Yang W, Lin DT, Yu CH, Kham S, Pui CH, Evans WE, Jeha S, Relling MV, Yeoh AE, Yang JJ. Novel variants in <i>NUDT15</i> and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. *Blood* 2017; **130**: 1209-1212 [PMID: 28659275 DOI: 10.1182/blood-2017-05-782383]

**P-Reviewer:** De Silva AP, Osawa S, Skok P **S-Editor:** Chen K **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Demographic data and treatment of 96 patients**

**Patient  *n***

Gender 32 females 64 males

Median age at presentation 28

Range 10-71

UC; CD 67; 29

Treatment

 6MP Yes 96 No 0

 5ASA Yes 90 No 6

 Steroid Yes 54 No 42

Anti-TNF drugs Yes 36 No 60

CD: Crohn’s disease.

**Table 2 Primer sequence for Sanger sequencing analysis of *NUDT15* exon 1 and exon 3**

|  |  |
| --- | --- |
| **Primer** | **Primer sequence** |
| *NUDT15* exon1 forward | 5’-CAAAGCACAACTGTAAGCGACT-3’ |
| *NUDT15* exon1 reverse | 5’-GAAAGACCCAGCTAGCAAAGAC-3’ |
| *NUDT15* exon3 forward | 5’-TTGTATAGCCAAGCAAATGCAAAGC-3’ |
| *NUDT15* exon3 reverse | 5’-TCTGTGTCTGGAATACAATTCAATGAC-3’ |

**Table 3 Genotypes of *NUDT15* and *TPMT***

**Patients Exon1 Exon 3 *TPMT***

Group A (*n =* 3)

#1-#3 c.52G > A Wild Wild

(p.Val18Ile)

Group B (*n =* 3)

#4-#6 c.36\_37insGGAGTC c.415C > T Wild

(p.Val18 Val19insGlyVal) (p.Arg139Cys)

Group C (*n =* 18)

#7-#24 　　Wild c.415C > T Wild

(p.Arg139Cys)

GroupD (*n =* 72)

#25-#96　　　　Wild 　　Wild Wild



**Figure 1 Change of white blood cell counts (Group A, B and C *vs* D).** A: Absolute number of WBC counts in two groups (Groups A, B and C *vs* D).WBC gradually decreased after the thiopurine was started in both the mutant (*n =* 24) and the wild type. The WBC count of the mutant was lower and statistically significant at 6, 8, 10 and 16 wk(*P =* 0.0271, 0.0037, 0.0051, and 0.0185, respectively).B: Decrease rate of the WBC counts in two groups (Groups A, B and C *vs* D).The decrease rate was higher in the variants (*n =* 24) than the wild (*n =* 72) and statistically significant at 4, 6, 8, 10, 12, 14 and 16 wk (*P =* 0.004, 0.0001, 0.0012, 0.0022, 0.00001, 0.0264 and 0.0031, respectively). We set 1.0 as the WBC count at the beginning of thiopurines.



**Figure 2 Change of white blood cell counts with or without prednisolone.** A: Absolute number of WBC counts in two groups (Groups A + B + C *vs* D) with PSL.In the cases with prednisolone, WBC count tended to decreased more in the mutant cases (Group A + B + C) and was significantly different at 8 and 10 wk (*P =* 0.012 and 0.029, respectively). B: Absolute number of WBC counts in two groups (Groups A + B + C *vs* D) without PSL.In the cases without prednisolone, WBC count was significantly lower at 2, 4, 8 and 14 wk significantly in the mutant (Group A + B + C) than the wild cases (Group D, *P =* 0.0196, 0.0182, 0.0237 and 0.0241, respectively). PSL: Prednisolone.



**Figure 3 Effect of thiopurine on white blood cell count.** A: Absolute number of WBC counts in three groups (Groups A + B *vs* C *vs* D) without PSL.We next divided cases into 3 categories: Group A + B, Group C and Group D. Group C was already reported cases with *NUDT15* c.415C > T in exon 3 in IBD cases. Group A + B included mutations in exon 1 which is not investigated in IBD. Group A + B and Group C was lower in WBC count and decrease rate than Group D.B: Decrease ratio of WBC counts in three groups (Groups A + B *vs* C *vs* D) without PSL**;** Group A + B and Group C was lower in WBC count and decrease rate than Group D; Group A + B and Group C was lower in decrease rate than Group D.



**Figure 4 Effect of thipourine on mean corpuscular volume.** A: MCV in Groups A + B + C *vs* D.MCV increased after starting 6MP in both the mutant (Group A + B + C) and the wild cases (Group D, Figure4a and b). MCV was significantly higher at 10 wk in the mutant than the wild cases (*P =* 0.0085).B: Increase ratio of MCV in Groups A + B + C *vs* D.The increase rate was higher in the variants than the wild and statistically significant at 16 wk (*P =* 0.00198). We set 1.0 as the MCV at the beginning of thiopurines. 6MP: 6-mercaptopurine.